Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference
Enanta Pharmaceuticals presented its strategy at the Citizens Life Sciences Conference, outlining Phase 3 plans for its RSV drug zelicapavir, targeting high-risk adults. The company also highlighted its second RSV candidate, EDP-323, which showed rapid viral load reduction, and announced expansion of its oral immunology pipeline with several small-molecule programs for mast cell-driven diseases and atopic dermatitis. Enanta reported a strong cash position of $242 million, providing funding into fiscal 2029 for these initiatives.